UCSF researchers report a new spatial repellent that provides up to one year of protection against malaria and other mosquito-borne diseases, marking the first WHO-endorsed vector control tool in over four decades.
New research by the American Heart Association finds that obesity is a factor in almost half of all new cases, with obese individuals significantly more likely to get Type 2 diabetes.
Experts from the International Agency for Research on Cancer and the University of Molise chart the impact of the COVID-19 pandemic on cancer treatment.
UK based scientists witnessed how COVID-19 can mutate in a highly vulnerable patient, even when that person is undergoing convalescent plasma treatment.
The Medicines Manufacturing Innovation Centre (MMIC) has developed a scalable, sustainable and more cost-effective way to manufacture oligonucleotides and treat rare diseases.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
According to data collected by 400 healthcare professionals at the worst moment of the US outbreak, the life support machine that acts in place of the heart and lungs is crucial to reducing COVID-19 deaths for the critically ill.
Engineers at the University of Bath have published a mathematical model that could help clinicians to safely ventilate two COVID patients on one ventilator.
Anna Forsberg, Professor of Transplant Nursing at Lund University and Chair of the ETAHP Committee at the ESOT, explores a key area of development in heart transplant nursing as part of the build-up to ESOT Congress 2021.
A new study revealing how ovarian cancer cells adapt to their environment to aid tumour growth brings researchers closer to developing targeted treatments.
Damaged heart muscle is a tragic possibility for patients of breast cancer chemotherapy - but thanks to Dr Husam Abdel-Qadir, there may now be a way to stop it.
Salk Institute scientists believe they have solved this mystery for bipolar disorder patients - the answer involves a specific gene, and proposes changes to the future of treatment.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
